Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Risk Stratification and Treatment of CLL: If New Drugs Available, 17p / TP53 Should Be Tested at 1st-Line and Relapse/Refractory

233 views
December 20, 2019
0 Comments
Login to view comments. Click here to Login
Hematologic Oncology